Childhood Cancer

Group leader: Jeanette Falck Winther

Our research is primarily focused on epidemiological studies of the late effects of cancer treatment in survivors of childhood and young adult cancer and their offspring. 
 
The collaborative research program Adult Life after Childhood Cancer in Scandinavia (ALiCCS) between the five Nordic countries was initiated in 2010 with the purpose of investigating somatic late effects from cancer therapy in children in the Nordic region. The overall goal for this program including 43 909 childhood cancer patients and five as many population-based comparisons is to obtain a better understanding of the mechanisms behind treatment-induced somatic diseases in different organ systems such as cardiovascular, pulmonary and endocrine disorders, which is critical for making evidence-based recommendations for future care of long-term survivors.

Childhood Cancer test

A strong collaboration has been established between leading research groups within this research area in both Europe and the US,  i.e. PanCareSurFup focusing on cardiac disease, subsequent primary neoplasms and late mortality in survivors as well as development of guidelines to improve lives for survivors (www.pancaresurfup.eu), PanCareLIFE focusing on female infertility, cisplatin-induced ototoxicity, and quality of life (www.pancarelife.eu), and PanCareFollowUp aiming at setting up state-of-the-art late effect clinics based on international guidelines for surveillance of late effects and a new innovative model for integrated care for survivors (www.pancarefollowup).  These European consortia are great examples of how collaboration across borders improve research especially when studying a rare disease such as childhood cancer.

Whereas an increasing body of evidence exists on somatic late effects in survivors, little is known about the socioeconomic and psychosocial impact of childhood cancer in long-term survivors. To address these knowledge gaps, the research program Socioeconomic consequences in Adult Life after Childhood Cancer in Scandinavia (SALiCCS) was initiated in 2016 with the overall aim of investigating socio-economic consequences in 20 000 long-term childhood cancer survivors in Denmark, Sweden and Finland. Findings of this research program will enrich our understanding of the difficulties young childhood cancer survivors encounter integrating into society, which can be used as the basis for development of future interventions targeting vulnerable subgroups of survivors – knowledge highly requested by the survivors and their families and of great value for the society as such.

Childhood Cancer test

The ultimate goal of these large research programs is to provide every childhood cancer survivor with better care and better long-term health so that they reach their full potential, and to the degree possible, enjoy the same quality of life and opportunities as their peers.  
 
Another main research area of interest is familial cancer syndromes affecting children 
and adolescents focusing on evaluating health-related and psychosocial consequences 
of neurofibromatosis type 1 (NF1). NF1 is one of the most common Mendelian diseases with a worldwide incidence of approximately one per 3000 individuals. We address the critical needs of the NF community in two important areas: cognitive and social dysfunction in the setting of NF and manifestations of NF post-adolescence.  


Selected publications:

Norsker FN, Rechnitzer C, Cederkvist L, Holmqvist AS, Tryggvadottir L, Madanat-Harjuoja L-M, Øra I, Thorarinsdottir HK, Vettenranta K, Bautz A, Schrøder H, Hasle H, Winther JF: Somatic late effects in 5-year survivors of neuroblastoma: a population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia study. Int J Cancer 2018;143(12):3083-3096 
 
Allodji RS, Hawkins MM, Bright CJ,  Fidler-Benaoudia MM, Winter DL, Alessi D, Fresneau B, Jouny N, Morsellino V, Bardi E, Bautz A, Byrne J, Am Feijen EL, Teepen JC, Vu-Bezin G, Rubino C, Garwicz S, Grabow D, Gudmundsdottir T, Guha J, Hau E-M, Jankovic M, Kaatsch P, Kaiser M, LInge H, Muraca M, Llanas D, Veres C, Øfstaas H, Diallo I, Mansouri I, Ronckers CM, Skinner R, Terenziani M, Wesenberg F, Wiebe T, Sacerdote C, Jakab Z, Haupt R, Lahteenmaki P, Zaletel LZ, Kuehni CE, Winther JF, Michel G, Kremer LCM, Hjorth L, Haddy N, de Vathaire F, Reulen RC: Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe: A cohort study within PanCareSurFup. Eur J Cancer 2019;117:71-83
 
Clemens E, Broer L, Langer T, Uitterlinden AG, de Vries ACH, van Grotel M, Pluijm SFM, Binder H, Byrne J, van Dulmen-den Broeder E, Crocco M, Grabow D, Kaatsch P, Kaiser M, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, van der Kooi A-L, Kremer LC, Kruseova J, Kuehni CE, van der Paal H, Parfitt R, Deuset D, Matulat P, Spix C, Tillmanns A, Tissing WJE, Maier L, Am Zehnhoff-Dinnesen A, Zolk O, van den Heuvel-Eibrink MM, PanCare LIFE consortium: Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study. Pharmacogenomics J 2020;20(2):294-305 
 
Frederiksen LE, Mader L, Feychting M, Mogensen H, Madanat-Harjuoja L, Malila N, Tolkkinen A, Hasle H, Winther JF, Erdmann F: Surviving childhood cancer: a systematic review of studies on risk and determinants of adverse socioeconomic outcomes. Int J Cancer 2019;144(8):1796-1823
 
Kenborg L, Duun-Henriksen AK, Dalton SO, Bidstrup PE, Doser K, Rugbjerg K, Pedersen C, Krøyer A, Johansen C, Andersen KK, Østergaard JR, Hove H, Sørensen SA, Riccardi VM, Mulvihill JJ, Winther JF: Multisystem burden of neurofibromatosis 1 in Denmark: registry- and population-based rates of hospitalizations over the life span. Genet Med 2020;22(6):1069-1078
 


 

Group leader Jeanette Falck Winther
Research profile

Contact
 


Childhood Cancer
Staff Members


Key Funding

Nordforsk

The Leo Foundation

Barncancerfonden